Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
A series of 7-(2-substituted-ethyl)amino analogues of mitomycin C and porfiromycin was prepared and screened in standard antitumor systems. Certain of these analogues showed better activity than mitomycin C against P-388 leukemia, L-1210 leukemia, and/or B-16 melanocarcinoma in mice. Compounds also tested for their leukopenic effects in mice, the limiting toxicity of mitomycin C. Some of them were less leukopenic and some were more leukopenic than this clinical agent. No statistically significant correlations could be made between physicochemical properties and antitumor activities of the analogues.
D000818:Animals; D005021:Ethylamines / Q000138:chemical synthesis / Q000494:pharmacology; D005260:Female; D007939:Leukemia L1210 / Q000188:drug therapy; D007941:Leukemia P388 / Q000188:drug therapy; D007970:Leukopenia / Q000139:chemically induced; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D008937:Mitomycins / Q000138:chemical synthesis* / Q000494:pharmacology; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011160:Porfiromycin / Q000031:analogs & derivatives / Q000138:chemical synthesis / Q000494:pharmacology; D013329:Structure-Activity Relationship
D005021:Ethylamines; D008937:Mitomycins; D011160:Porfiromycin